Latus Bio Secures $97M Series A to Advance Gene Therapy Pipeline for Neurodegenerative Diseases
核心洞察
Latus Bio (搜索) closed a $97 million Series A financing round to accelerate its clinical pipeline targeting neurodegenerative conditions with novel AAV capsid technology.
The company's proprietary AAV-DB-3 (搜索) capsid can transduce deep brain structures at doses 10-100 fold lower than current industry standards, according to preclinical data published in Nature Communications.
Lead programs include LTS-201 (搜索) for Huntington's disease (搜索) with IND submission planned for Q3 2026, and LTS-101 (搜索) for CLN2 disease (搜索) which has already received FDA IND clearance and multiple regulatory designations.
Latus Bio (搜索) has closed a $97 million Series A financing round to accelerate development of its gene therapy pipeline targeting devastating neurodegenerative conditions that have long eluded effective treatment due to delivery challenges. The oversubscribed round demonstrates growing investor enthusiasm for "Gene Therapy 2.0" technologies that extend beyond the constraints of initial viral delivery solutions.
The biotechnology company aims to overcome longstanding barriers in central nervous system (CNS) gene delivery through the design of highly specialized adeno-associated virus (AAV) capsids. Traditional AAV serotypes face difficulty penetrating brain structures or require large doses that risk systemic toxicity and adverse effects.
Breakthrough in Deep Brain Delivery
Latus Bio (搜索) believes it has overcome this barrier through a unique discovery engine that searched 6.8 million capsid variants to identify a lead candidate labeled AAV-DB-3 (搜索). Preclinical data published in Nature Communications indicated that this vector was capable of transducing deep brain structures, such as the basal ganglia, at doses 10-100 fold lower than current industry standards.
"This financing supports our strategy to expand gene therapy to larger diseases that affect millions of patients," said Dr. P. Peter Ghoroghchian, CEO of Latus Bio (搜索). "By combining engineered capsids with optimal delivery routes, we aim to achieve specific targeting at ultra-low doses, which is the key to improving safety and reducing manufacturing costs."
Clinical Pipeline Advancement
The $97 million will primarily fund advancement of Latus Bio (搜索)'s two lead programs:
LTS-201 (搜索) for Huntington's Disease (搜索): This investigational AAV gene therapy is designed to knock down the MSH3 (搜索) gene, which drives the underlying process of somatic instability in Huntington's disease. The candidate targets medium spiny neurons (搜索) through a single, precise, deep brain injection intended to halt disease progression. An Investigational New Drug (IND) submission is planned for Q3 2026. Huntington's disease affects greater than 100,000 patients in major gene therapy markets and currently has no approved disease-modifying therapies.
LTS-101 (搜索) for CLN2 Disease (搜索): This program, directed at a rare but fatal pediatric neurodegenerative disorder, has secured IND clearance from the FDA along with Orphan Drug Designation, Rare Pediatric Disease Designation, and Fast Track Designation. Initiation of a first-in-human investigator-initiated trial is expected in the third quarter of 2026, with initial safety, biomarker and clinical results expected by year-end.
Beyond these specific programs, the company is leveraging its database of delivery capabilities to diversify into other diseases, including Parkinson's disease (搜索) and conditions affecting the kidney, eye, and heart.
Strategic Investment and Platform Validation
The Series A was co-led by 8VC (搜索) and DCVC Bio (搜索), with participation from 14 other institutional investors including Korea Development Bank and Helen's Pink Sky Foundation as new investors. The financing includes a $43 million extension led by 8VC.
"Investor support for this financing reflects conviction in Latus' differentiated and scalable approaches to gene therapy," said Francisco Gimenez, Partner at 8VC (搜索). "The Company's strategy to focus on large-rare and broader CNS indications, combined with its novel capsid engineering and clinically-grounded delivery approach, positions it to address longstanding limitations to gene therapy access."
Kiersten Stead noted that "Latus Bio (搜索) isn't just making incremental improvements; they are rewriting the delivery rules for CNS therapies. Their ability to reach specific cell types at a fraction of the traditional dose changes the economic and safety profile."
The company maintains facilities in both Philadelphia and Boston's Seaport District, with technologies derived from the Philadelphia ecosystem. Latus plans to pursue strategic partnerships to further expand its platform for discovering novel capsid variants and to address non-core and non-CNS indications.